253 related articles for article (PubMed ID: 24563621)
1. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression.
Chen CS; Doloff JC; Waxman DJ
Neoplasia; 2014 Jan; 16(1):84-96. PubMed ID: 24563621
[TBL] [Abstract][Full Text] [Related]
2. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.
Wu J; Waxman DJ
Cancer Lett; 2014 Oct; 353(2):272-80. PubMed ID: 25069038
[TBL] [Abstract][Full Text] [Related]
3. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.
Wu J; Jordan M; Waxman DJ
BMC Cancer; 2016 Aug; 16():623. PubMed ID: 27515027
[TBL] [Abstract][Full Text] [Related]
4. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression.
Doloff JC; Waxman DJ
Cancer Res; 2012 Mar; 72(5):1103-15. PubMed ID: 22237627
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2.
Doloff JC; Chen CS; Waxman DJ
Mol Cancer; 2014 Jun; 13():158. PubMed ID: 24965046
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts.
Doloff JC; Waxman DJ
BMC Cancer; 2015 May; 15():375. PubMed ID: 25952672
[TBL] [Abstract][Full Text] [Related]
7. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
Shiraga E; Barichello JM; Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
[TBL] [Abstract][Full Text] [Related]
8. Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer.
Wang R; Qin S; Chen Y; Li Y; Chen C; Wang Z; Zheng R; Wu Q
Oncol Rep; 2012 Aug; 28(2):439-45. PubMed ID: 22641525
[TBL] [Abstract][Full Text] [Related]
9. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
Kerbel RS; Shaked Y
Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
[TBL] [Abstract][Full Text] [Related]
10. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8
Wu J; Waxman DJ
Oncoimmunology; 2015 Apr; 4(4):e1005521. PubMed ID: 26137402
[TBL] [Abstract][Full Text] [Related]
11. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.
Ma J; Waxman DJ
Mol Cancer Ther; 2008 Jan; 7(1):79-89. PubMed ID: 18202011
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGylated liposomes in a murine solid tumor model.
Ishida T; Shiraga E; Kiwada H
J Control Release; 2009 Mar; 134(3):194-200. PubMed ID: 19095022
[TBL] [Abstract][Full Text] [Related]
14. Increased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine.
Doloff JC; Khan N; Ma J; Demidenko E; Swartz HM; Jounaidi Y
Curr Cancer Drug Targets; 2009 Sep; 9(6):777-88. PubMed ID: 19754361
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
[TBL] [Abstract][Full Text] [Related]
16. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models.
Daenen LG; Shaked Y; Man S; Xu P; Voest EE; Hoffman RM; Chaplin DJ; Kerbel RS
Mol Cancer Ther; 2009 Oct; 8(10):2872-81. PubMed ID: 19825805
[TBL] [Abstract][Full Text] [Related]
17. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
Hashimoto K; Man S; Xu P; Cruz-Munoz W; Tang T; Kumar R; Kerbel RS
Mol Cancer Ther; 2010 Apr; 9(4):996-1006. PubMed ID: 20371722
[TBL] [Abstract][Full Text] [Related]
18. Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models.
Du B; Waxman DJ
Cancer Lett; 2020 Feb; 470():170-180. PubMed ID: 31765733
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice.
Emmenegger U; Shaked Y; Man S; Bocci G; Spasojevic I; Francia G; Kouri A; Coke R; Cruz-Munoz W; Ludeman SM; Colvin OM; Kerbel RS
Mol Cancer Ther; 2007 Aug; 6(8):2280-9. PubMed ID: 17671082
[TBL] [Abstract][Full Text] [Related]
20. Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis.
Jia L; Waxman DJ
Cancer Lett; 2013 Apr; 330(2):241-9. PubMed ID: 23228633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
